Eli Lilly and Company: Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRa-targeting ADC at ESMO 2026

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity ...
PR Newswire

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with ...

The Origin of Life | The Intelligence Revolution of the 〈Mind〉 [Compilation-5]

Why Were We Born?[Summary] 1-1-2 The Origin of LifeThe origin of life has not been determined even by experts, and while the ...